Gumieniczek A, Berecka-Rycerz A. Metabolism and Chemical Degradation of New Antidiabetic Drugs: A Review of Analytical Approaches for Analysis of Glutides and Gliflozins. Biomedicines. 2023;11:2127 https://doi.org/10.3390/biomedicines11082127.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang W, Li X, Ding H, Lu Y, Stilwell GE, Halvorsen Y-D, et al. Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans. Xenobiotica. 2020;50:559–69. https://doi.org/10.1080/00498254.2019.1654634.

Article  CAS  PubMed  Google Scholar 

Quattrin T, Mastrandrea LD, Walker LSK. Type 1 diabetes. Lancet. 2023;401:2149–62. https://doi.org/10.1016/s0140-6736(23)00223-4.

Article  CAS  PubMed  Google Scholar 

Karnchanasorn R, Huang J, Ou H-Y, Feng W, Chuang L-M, Chiu KC, et al. Comparison of the Current Diagnostic Criterion of HbA1c with Fasting and 2-Hour Plasma Glucose Concentration. J Diab Res. 2016;2016:1–11. https://doi.org/10.1155/2016/6195494.

Article  CAS  Google Scholar 

Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521 https://doi.org/10.3389/fendo.2023.1161521.

Article  Google Scholar 

El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action. World J Diab. 2021;12:1401–25. https://doi.org/10.4239/wjd.v12.i9.1401.

Article  Google Scholar 

Zhou X, Shrestha SS, Shao H, Zhang P. Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005–2007 and 2015–2017. Diab Care. 2020;43:2396–402. https://doi.org/10.2337/dc19-2273.

Article  Google Scholar 

Taylor SI. The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients. Diab Care. 2020;43:2330–2. https://doi.org/10.2337/dci20-0039.

Article  Google Scholar 

Bexagliflozin (Brenzavvy) - A fifth SGLT2 inhibitor for type 2 diabetes. Med Lett Drugs Ther. 2023;65:130–2. https://doi.org/10.58347/tml.2023.1683b.

Aggarwal R, Vaduganathan M, Chiu N, Bhatt DL. Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. Circulation: Heart Fail. 2022;15. https://doi.org/10.1161/circheartfailure.121.009099.

Hoy SM. Bexagliflozin: First Approval. Drugs. 2023;83:447–53. https://doi.org/10.1007/s40265-023-01848-x.

Article  CAS  PubMed  Google Scholar 

Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diab Obes. 2017;24:73–9. https://doi.org/10.1097/med.0000000000000311.

Article  CAS  Google Scholar 

Cowart K, Coon S, Carris NW. A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes. Ann Pharmacotherapy. 2023. https://doi.org/10.1177/10600280231190443.

Dalal D, Kant R, Attri K, Kapoor G, Nagarajan K, Bhutani R, et al. A Systematic Overview of Bexagliflozin: A Type 2 Diabetic Drug. Asian J Pharmaceutical Res Health Care. 2023;15:109–14.

Azzam O, Carnagarin R, Lugo-Gavidia LM, Nolde J, Matthews VB, Schlaich MP. Bexagliflozin for type 2 diabetes: an overview of the data. Expert Opin Pharmacother. 2021;22:2095–103. https://doi.org/10.1080/14656566.2021.1959915.

Article  CAS  PubMed  Google Scholar 

Allegretti AS, Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, et al. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD. Am J Kidney Dis. 2019;74:328–37. https://doi.org/10.1053/j.ajkd.2019.03.417.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dholariya S, Dutta S, Singh R, Parchwani D, Sonagra A, Kaliya M. Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis. Expert Opin Pharmacotherapy. 2023. https://doi.org/10.1080/14656566.2023.2269854.

Frak W, Hajdys J, Radzioch E, Szlagor M, Mlynarska E, Rysz J, et al. Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors. Biomedicines. 2023;11. https://doi.org/10.3390/biomedicines11072085.

Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377:644–57. https://doi.org/10.1056/nejmoa1611925.

Article  CAS  PubMed  Google Scholar 

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, Von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375:323–34. https://doi.org/10.1056/nejmoa1515920.

Article  CAS  PubMed  Google Scholar 

Halvorsen Y-D, Walford G, Thurber T, Russell H, Massaro M, Freeman MW. A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. Diab Obes Metab. 2020;22:566–73. https://doi.org/10.1111/dom.13928.

Article  CAS  Google Scholar 

Halvorsen Y-D, Lock JP, Zhou W, Zhu F, Freeman MW. A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diab Obes Metab. 2019;21:2248–56. https://doi.org/10.1111/dom.13801.

Article  CAS  Google Scholar 

Halvorsen YD, Lock JP, Frias JP, Tinahones FJ, Dahl D, Conery AL, et al. A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diab Obes Metab. 2023;25:293–301. https://doi.org/10.1111/dom.14875.

Article  CAS  Google Scholar 

Lin J, Wang S, Wen T, Zhang X. Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus: a network meta-analysis and systematic review. Int Urol Nephrol. 2022;54:2305–16. https://doi.org/10.1007/s11255-022-03117-4.

Article  CAS  PubMed  Google Scholar 

Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018;14:1287–302. https://doi.org/10.1080/17425255.2018.1551877.

Article  CAS  PubMed  Google Scholar 

Sen T, Heerspink HJL. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab. 2021;33:732–9. https://doi.org/10.1016/j.cmet.2021.02.016.

Article  CAS  PubMed  Google Scholar 

Feng M, Lv H, Xu X, Wang J, Lyu W, Fu S. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicine. 2019;98:e16575 https://doi.org/10.1097/md.0000000000016575.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14 https://doi.org/10.1186/s12933-015-0314-0.

Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diab Endocrinol. 2013;1:208–19. https://doi.org/10.1016/S2213-8587(13)70084-6.

Article  CAS  Google Scholar 

Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diab, Obes Metab. 2013;15:372–82. https://doi.org/10.1111/dom.12054.

Article  CAS  Google Scholar 

Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diab, Obes Metab. 2017;19:721–8. https://doi.org/10.1111/dom.12888.

Article  CAS  Google Scholar 

Basak D, Gamez D, Deb S. SGLT2 Inhibitors as Potential Anticancer Agents. Biomedicines. 2023;11:1867 https://doi.org/10.3390/biomedicines11071867.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saisho Y. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes? Diseases. 2020;8 https://doi.org/10.3390/diseases8020014.

Lymperopoulos A, Borges JI, Cora N, Sizova A. Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin’s Effects in the Adrenal Gland. Int J Mol Sci. 2021;22:7684 https://doi.org/10.3390/ijms22147684.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S, et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci USA. 2011;108:8030–5. https://doi.org/10.1073/pnas.1016088108.